Press Release | Thu Jul 25, 2013 5:00pm EDT

U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes

* Reuters is not responsible for the content in this press release.